| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000002382 |
| Receipt No. | R000002927 |
| Official scientific title of the study | To prevent low-dose aspirin induced peptic ulcers, which is better the use of proton pump inhibitors or histamine type2 receptor agonist; randomized controlled trial |
| Date of disclosure of the study information | 2009/09/04 |
| Last modified on | 2017/07/29 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | To prevent low-dose aspirin induced peptic ulcers, which is better the use of proton pump inhibitors or histamine type2 receptor agonist; randomized controlled trial | |
| Title of the study (Brief title) | To prevent low-dose aspirin induced peptic ulcers, which is better the use of PPI or H2RA | |
| Region |
|
|
| Condition | ||||||
| Condition | the patients who are taking low dose aspirin | |||||
| Classification by specialty |
|
|||||
| Classification by malignancy | Others | |||||
| Genomic information | NO | |||||
| Objectives | |
| Narrative objectives1 | It is said that to prevent low-dose aspirin induced peptic ulcers, proton pump inhibitors (PPI) is effective. In Western contries, it is said that taking histamine-2 receptor antagonists (H2RA) is effective to prevent those ulcers. It is necessary to prove that conclusion is truth or not in Japan. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | with or without peptic ulcer on the patients who are taking low dose aspirin |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | famotidine 40mg/day | |
| Interventions/Control_2 | lansoprazole 15mg/day | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patient who fills everything the following
1)Patients who are taking low-dose aspirin 2) Patient of 20 years or older and 90 years or younger 3) Patient who gives written informed consent |
|||
| Key exclusion criteria | The patient who collides with either the following assumes that it doesn't put it in to the examination
1) Drug allergy 2)Patient who have taken PPI 3)Patient who have taken clopidogrel, antifungal agent, and corticosteroid 4)Patient who have malignant neoplasm 5)Patient who is postgastrectomy 6)pregnant and lactation 7)Liver disorder, renal disorder, bronchial asthma |
|||
| Target sample size | 400 | |||
| Research contact person | |
| Name of lead principal investigator | Atsushi Nakajima |
| Organization | Yokohama City University Graduate School of Medicine |
| Division name | Gastroenterology Division |
| Address | 3-9 Fuku-ura, Kanagawa-ku, Yokohama, Japan |
| TEL | |
| Public contact | |
| Name of contact person | Masahiko Inamori |
| Organization | Yokohama City University Graduate School of Medicine |
| Division name | Gastroenterology Division |
| Address | 3-9 Fuku-ura, Kanagawa-ku, Yokohama, Japan |
| TEL | |
| Homepage URL | |
| Sponsor | |
| Institute | Gastroenterology Division, Yokohama City University Graduate School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002927 |